Voisin Consulting Life Sciences webinar icon
Webinar

Getting an Early Access Program Off the Ground Safely

Post thumbnail Getting an Early Access Program Off the Ground Safely

Embracing an Early Access Program (EAP) presents a strategic avenue for creating valuable opportunities for patients and companies.

This webinar explores the strategic advantages of implementing an Early Access Program, highlighting how it serves as a dynamic tool to engage with patients and collaborate with payers.

It aims at getting a better understanding of key benefits and considerations, including the role of safety, providing insights into how organizations can effectively leverage Early Access Programs to foster innovation, refine offerings, broaden the possibilities of safety data collection, tap into market-like populations, and create meaningful opportunities in the market.

Voisin Consulting Life Sciences download icon

Access the full webinar replay now

Fill in the form to download the content

    Yes, I would like to receive communications regarding VCLS services and events

    Sample of the webinar

    Featured Speakers

    Adeline Darchy, M.Sc thumbnail
    Adeline Darchy, M.Sc
    Director, Clinical Research
    Adeline is the Director of the Clinical Operations. She has a deep understanding of program management principles and regulatory requirements. Adeline actively engages with key stakeholders to guarantee the compliant execution of Early Access Program objectives. This involves addressing inquiries from healthcare practitioners, streamlining the review and approval process for Early Access Program protocols, and managing associated documents. Her strategic approach ensures the effective establishment of Early Access Programs.
    Voisin Consulting Life Sciences default post thumbnail
    Hayley Marsh
    Senior Vigilance Scientist
    Hayley leads the Health Authority Admin, QPPV Office and Vigilance Regulatory Surveillance team at VCLS. Hayley’s extensive vigilance experience spans both the clinical and post-market spheres of drug development.